Seres Therapeutics Inc. (NASDAQ:MCRB) saw an upside of 0.47% to close Tuesday at $6.46 after adding $0.03 on the day. The 5-day average trading volume is 966,720 shares of the company’s common stock. It has gained $6.60 in the past week. An average of 1,832,795 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,832,080.
MCRB’s 1-month performance is 9.68% or $0.19 on its low of $5.41 reached on 09/14/21. The company’s shares have touched a 52-week low of $5.41 and high of $38.50, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, MCRB has lost -73.63% or -$18.04. However, the current price is down -83.22%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Dec 01, 316 days have gone by since the last insider trading activity for Seres Therapeutics Inc. (MCRB). Henn Matthew R. (See Remarks) most recently sold 91,812 shares at $27.04 per share on Dec 01. This transaction cost the insider $2,482,309.
Seres Therapeutics Inc. (MCRB) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.MCRB stock has a beta of 3.81. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 20.06 while the price-to-book (PB) in the most recent quarter is 5.87.
Seres Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.00, with the current ratio over the same period at 4.00 meaning that MCRB stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.19, while the total debt to equity was 0.25The trailing 12-month EBITDA margin is -238.56%. The firm’s gross profit as reported stood at $121.34 million against revenue of $33.22 million.
For the quarterly period ending June 29 this year, Seres Therapeutics Inc.’s cash and short-term investments amounted to $140.56 million against total debt of $44.84 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected MCRB to announce -$0.37 per share in earnings in its latest quarter, but it posted -$0.53, representing a -43.20% surprise. EBITDA for the quarter stood at more than -$45.99 million. MCRB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 168.58 million, with total debt at $44.84 million. Shareholders hold equity totaling $91.72 million
Let’s look briefly at Seres Therapeutics Inc. (MCRB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 44.31% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.54%.
The stock’s 5-day moving average is $6.39, reflecting a unch or $unch change from its current price. MCRB is currently trading +18.32% above its 20-day SMA, -70.30% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -8.11% and -73.39% respectively.
Stochastic %K and %D was 21.64% and 19.98% and the average true range (ATR) pointed at 0.36. The RSI (14) points at 43.69%, while the 14-day stochastic is at 26.32% with the period’s ATR at 0.40. The stock’s 9-day MACD Oscillator is pointing at -0.21 and -0.34 on the 14-day charts.
In the most recent analyst report for Seres Therapeutics Inc. (NASDAQ: MCRB), Goldman downgraded it to a Sell rating. They previously had a Neutral rating on the stock. Analysts offering their rating for MCRB stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate MCRB as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is MCRB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $32.00, with their median price target at $19.00. Looking at these predictions, the average price target given by analysts is for Seres Therapeutics Inc. (MCRB) stock is $20.57.